[Adhesion molecules in the context with bone remodeling and osteoporosis].
Tanaka
Yoshiya
Y
First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
D000818:Animals; D001857:Bone Matrix / Q000378:metabolism; D016723:Bone Remodeling / Q000235:genetics* / Q000502:physiology; D002448:Cell Adhesion / Q000235:genetics / Q000502:physiology; D015815:Cell Adhesion Molecules / Q000502:physiology*; D002454:Cell Differentiation / Q000235:genetics / Q000502:physiology; D018925:Chemokines / Q000502:physiology; D016207:Cytokines / Q000502:physiology; D006023:Glycoproteins / Q000502:physiology; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D010006:Osteoblasts / Q000166:cytology / Q000502:physiology; D010010:Osteoclasts / Q000166:cytology / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology*; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor
D015815:Cell Adhesion Molecules; D018925:Chemokines; D016207:Cytokines; D006023:Glycoproteins; D018836:Inflammation Mediators; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human